Management of Bicuspid Aortic Valve

Initial Diagnostic Evaluation

• The American College of Cardiology recommends comprehensive transthoracic echocardiography at diagnosis to assess valve function and measure aortic dimensions at multiple levels: annulus, sinuses of Valsalva, sinotubular junction, and mid-ascending aorta 1, 2
• Echocardiographic assessment should include measurement of aortic dimensions at four critical levels: aortic annulus, sinuses of Valsalva, sinotubular junction, and mid-ascending aorta 1
• Valve morphology should be assessed to determine cusp fusion pattern, as fusion involving the noncoronary cusp carries higher risk of aortic dilation (68% versus 40%) 1
• Doppler interrogation of the proximal descending aorta should be performed to evaluate for associated aortic coarctation 1
• The American Heart Association recommends quantifying stenosis severity using standard gradients and valve area, or regurgitation severity using standard parameters 2

Advanced Imaging

• Cardiac MRI or CT angiography should be obtained when echocardiography cannot adequately visualize the ascending aorta beyond 4.0 cm from the valve plane 2, 3
• The American College of Cardiology recommends MRI over CT to avoid cumulative radiation exposure in patients requiring lifelong surveillance 2

Family Screening

• First-degree relatives should be screened with echocardiography, as 20-30% will have bicuspid valve disease or associated aortopathy 1, 2
• Screening is clearly indicated if the patient has aortopathy or family history of valvular heart disease or aortopathy 1

Surveillance Strategy

• For aortic dimensions 4.0-4.5 cm, serial imaging (echocardiography, MRI, or CT) should be performed at intervals determined by rate of progression and family history 4, 3
• For aortic dimensions >4.5 cm, annual imaging with echocardiography, MRI, or CT angiography should be performed 4, 3, 5
• Expected progression rates are 0.5 mm/year at sinuses and sinotubular junction, 0.9 mm/year at proximal ascending aorta (though rates up to 2 mm/year have been reported) 4, 6

Medical Management

• Hypertension should be controlled with any effective antihypertensive agent 4, 6
• Beta-blockers and ARBs have theoretical advantages but lack proven benefit in clinical studies for slowing aortic dilation 4, 6, 3
• No proven medical therapies exist to reduce progression of BAV-associated aortopathy 4, 6

Surgical Indications

• Operation is indicated when aortic diameter exceeds 5.5 cm at any level (sinuses, sinotubular junction, or ascending aorta) 4, 6, 3
• Earlier intervention (5.0-5.5 cm) is recommended if family history of aortic dissection OR rapid progression ≥0.5 cm/year 7, 6, 8
• The American College of Cardiology recommends replacing ascending aorta when diameter exceeds 4.5 cm in patients undergoing aortic valve replacement for severe stenosis or regurgitation 7, 8, 9

Critical Pitfalls to Avoid

• The American Heart Association recommends not relying solely on echocardiography if the ascending aorta cannot be visualized adequately—obtain MRI or CT 2, 3
• The American College of Cardiology recommends not missing the cusp fusion pattern—patients with noncoronary cusp involvement have higher risk of extensive aortic dilation extending to the transverse arch 1, 2
• Doppler interrogation of the descending aorta should be performed to evaluate for aortic coarctation 1
• Family screening should not be delayed—20-30% of first-degree relatives are affected 1, 2
• The absolute risk of dissection remains low (3.1 per 10,000 patient-years), though 8.4 times higher than age-matched controls 4, 6

Blood Pressure Management in Ascending Aortic Dilatation

Rationale for Aggressive Blood‑Pressure Control

• In patients with thoracic aortic disease, an ascending aortic diameter of ≈5 cm marks a threshold at which the annual risk of rupture or dissection becomes clinically significant; therefore, medical therapy should aim to lower hemodynamic stress on the aortic wall【10】.
• Systolic pressures of 140–158 mmHg exceed the recommended target for thoracic aortic disease, representing inadequately controlled hypertension even though such values might be acceptable in other conditions【10】.
• Hypertension in the setting of aortic dilatation should be treated with any effective antihypertensive agent; beta‑blockers and angiotensin‑receptor blockers (ARBs) are favored for their theoretical benefits on wall stress, although definitive trial data demonstrating slowed aortic growth are lacking【11】.

Target Blood‑Pressure Goals

• The European Society of Cardiology (as reported in the European Heart Journal) recommends a systolic blood‑pressure goal <120 mmHg for patients with ascending aortic dilatation to minimize wall stress【12】.
• Combination antihypertensive therapy is often required to achieve the <120 mmHg target in this population【12】.

Preferred Pharmacologic Regimens

• Beta‑blockers are suggested as first‑line agents because they lower both systolic pressure and the rate of pressure change (dP/dt), thereby reducing pulsatile stress on the aortic wall (American Heart Association, Circulation)【13】.
• ARBs are a reasonable alternative or adjunct, offering theoretical advantages in aortic wall remodeling; however, clinical evidence for aortic‑size reduction remains limited (American Heart Association, Circulation)【11】.

Immediate Management Steps (Evidence‑Based)

• Initiate or intensify antihypertensive therapy with the goal of achieving systolic <120 mmHg, preferentially using beta‑blockers or ARBs (American Heart Association, Circulation)【11】【13】.
• Do not consider a systolic range of 140–158 mmHg as acceptable control in aortic dilatation; this level constitutes a modifiable risk factor that must be aggressively treated (European Society of Cardiology, European Heart Journal)【12】.
• Recognize that a diastolic pressure around 60 mmHg may signal significant aortic regurgitation, influencing both medical and surgical decision‑making (European Society of Cardiology, European Heart Journal)【12】.

Strength of evidence: Recommendations are based on expert consensus and observational data; no randomized controlled trials directly addressing optimal blood‑pressure targets in ascending aortic dilatation are cited.